Immune Thrombocytopenia Clinical Trials

84 recruitingLast updated: June 18, 2026

There are 84 actively recruiting immune thrombocytopenia clinical trials across 37 countries. Studies span Phase 2, Phase 1, Not Applicable, Phase 3, Phase 4, Early Phase 1. Top locations include Tianjin, Tianjin Municipality, China, Tianjin, China, Beijing, Beijing Municipality, China. Updated daily from ClinicalTrials.gov.


Immune Thrombocytopenia Trials at a Glance

84 actively recruiting trials for immune thrombocytopenia are listed on ClinicalTrialsFinder across 6 cities in 37 countries. The largest study group is Phase 2 with 36 trials, with the heaviest enrollment activity in Tianjin, Tianjin, and Beijing. Lead sponsors running immune thrombocytopenia studies include Institute of Hematology & Blood Diseases Hospital, China, Peking University People's Hospital, and University Hospital, Bordeaux.

Browse immune thrombocytopenia trials by phase

Treatments under study

About Immune Thrombocytopenia Clinical Trials

Looking for clinical trials for Immune Thrombocytopenia? There are currently 33 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Immune Thrombocytopenia trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Immune Thrombocytopenia clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 84 trials

Recruiting
Phase 2Phase 3

A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)

Immune Thrombocytopenic PurpuraITPIdiopathic Thrombocytopenic Purpura+4 more
argenx24 enrolled10 locationsNCT07194850
Recruiting
Phase 2

A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)

Primary Immune Thrombocytopenia (ITP)Primary Evans Syndrome (ES)
Novartis Pharmaceuticals164 enrolled2 locationsNCT07421167
Recruiting
Phase 1

RN1201 Injection in the Treatment of Antibody-Mediated Diseases

Refractory Immune-mediated Platelet Transfusion RefractorinessRelapsed or Refractory Immune Thrombocytopenia
The First Affiliated Hospital of Soochow University9 enrolled1 locationNCT07072247
Recruiting
Phase 2

Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab

Warm Autoimmune Hemolytic AnemiaPrimary immune thrombocytopenia
Novartis Pharmaceuticals60 enrolled22 locationsNCT07039422
Recruiting
Not Applicable

Contribution of Anti-platelet Antibodies Identified With MAIPA Assay in the Demonstration of the Auto-immune Character of a Thrombocytopenia at Diagnosis

ThrombocytopeniaImmune ThrombocytopeniaMyelodysplasia
University Hospital, Bordeaux225 enrolled1 locationNCT04800458
Recruiting
Phase 2

Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders

Immune Thrombocytopenia
Incyte Corporation56 enrolled40 locationsNCT07104565
Recruiting
Phase 2

Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia

Immune Thrombocytopenia (ITP)
Nuvig Therapeutics, Inc.30 enrolled1 locationNCT07095127
Recruiting
Phase 1

IASO-782 in Autoimmune Hematological Diseases

Autoimmune ThrombocytopeniaWarm Autoimmune Haemolytic Anaemia
Shanghai IASO Biotechnology Co., Ltd16 enrolled2 locationsNCT06534021
Recruiting
Phase 1

Phase I Study of SHR-2173 Injection in Patients With Primary Immune Thrombocytopenia

Immune Thrombocytopenia
Guangdong Hengrui Pharmaceutical Co., Ltd10 enrolled1 locationNCT07206758
Recruiting
Phase 3

Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment

Immune Thrombocytopenia
Sanofi60 enrolled30 locationsNCT07007962
Recruiting
Phase 1

Safety and Efficacy of GL-2045 in Patients With Immune Thrombocytopenia

Immune Thrombocytopenia
Gliknik Inc.42 enrolled1 locationNCT07605845
Recruiting
Phase 1Phase 2

A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia

Immune Thrombocytopenia (ITP)
Eli Lilly and Company58 enrolled45 locationsNCT06721013
Recruiting
Phase 2

Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia

Primary immune thrombocytopenia
Pfizer91 enrolled31 locationsNCT05070845
Recruiting
Phase 3

A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia

Primary Immune Thrombocytopenia (ITP)
argenx69 enrolled94 locationsNCT06544499
Recruiting
Phase 4

Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in Adults

Primary Immune Thrombocytopenia (ITP)
Institute of Hematology & Blood Diseases Hospital, China224 enrolled1 locationNCT04518475
Recruiting
Phase 3

High-Dose Dexamethasone Combined With Orelabrutinib Versus High-Dose Dexamethasone Combined With Placebo in Adult Patients With Newly Diagnosed Primary Immune Thrombocytopenia

Primary Immune Thrombocytopenia (ITP)
Shandong University86 enrolled1 locationNCT07559331
Recruiting
Phase 3

An Open-label Study of Intravenous Immunoglobulin (5%) for the Treatment of Primary Immune Thrombocytopenia

Primary Immune Thrombocytopenia (ITP)
Grand Shuyang Life Sciences (Chengdu) Co., Ltd.36 enrolled9 locationsNCT07233213
Recruiting
Phase 1

Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)

Antiphospholipid Syndrome (APS)Immune-mediated Necrotizing Myopathy (IMNM)Immune Thrombocytopenia (ITP)+3 more
Chugai Pharmaceutical144 enrolled69 locationsNCT06371417
Recruiting
Phase 1Phase 2

A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP)

ITPImmune Thrombocytopenia (ITP)Monoclonal+2 more
Climb Bio, Inc.24 enrolled20 locationsNCT07043946
Recruiting
Phase 3

A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)

Chronic Primary Immune Thrombocytopenia (ITP)
Kedrion S.p.A.40 enrolled27 locationsNCT07059000